CTIC - CTI BioPharma Corp.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

CTI BioPharma Corp.

3101 Western Avenue
Suite 800
Seattle, WA 98121
United States

Full Time Employees46

Key Executives

NameTitlePayExercisedYear Born
Dr. Adam R. CraigPres, CEO, Interim Chief Medical Officer & Director883.58kN/A1966
Mr. David H. KirskeExec. VP, CFO & Sec.480.75kN/A1954
Mr. Bruce J. SeeleyExec. VP & COO582.25kN/A1964
Mr. Ed BellSr. Director of Investor RelationsN/AN/AN/A
Mr. Jim FongSr. VP of US Commercial OperationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; University of Vermont; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

Corporate Governance

CTI BioPharma Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.